Futura’s Fast-Acting Topical Gel for the Treatment of Erectile Dysfunction Granted Marketing Authorisation by the US FDA for Over-the-Counter Sale
Futura Medical PLC (AIM:FUM) Highly positive FM71 Phase 3 Study Results
Highly positive FM71 Phase 3 Study Results with all primary and secondary endpoints achieved, MED3000 remains on track to obtain US FDA marketing authorisation
Futura Medical PLC (AIM:FUM) MED3000 Collaboration in EEA, UK & Switzerland
Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland
Futura Medical PLC (FUM.L) Notice of AGM and Annual Report
Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused
Futura Medical PLC (FUM.L) US FDA Agreement for Confirmatory Clinical study
Futura Medical Receives US FDA Agreement for Confirmatory Clinical study, FM71 for MED3000
Futura Medical PLC (FUM.L) Futura Announces Investment & Joint Collaboration
Futura Medical Announces Investment and Joint Collaboration to Commercialise MED3000 in China and South East Asia